Amphastar Pharmaceuticals, Inc. (AMPH) Dividend History

Company News

• Global Antidote Market to Cross the USD 4 Billion Mark by 2032 | DelveInsight

  The dilated cardiomyopathy market is witnessing substantial growth, driven by advancements in cardiovascular therapies and the increasing incidence of the condition. Key factors contributing to the market's upward momentum include greater public awareness, government initiatives, and continuous progress in product innovation.

  GlobeNewswire Inc.

  Featured Companies: AMRX
• JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability

  The specialty pharma sector is showing signs of stability, with modest growth and valuations recovering to historical averages. JP Morgan is most interested in Teva and Organon, maintaining a neutral rating on Teva due to its branded pipeline and caution about its U.S. generic business, while giving an underweight rating to Organon due to its recent stock price surge.

  Benzinga

  Featured Companies: AMRX OGN PRGO VTRS
• HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View - Zacks Investment Research

  HCA Healthcare reported strong Q2 2024 results, with adjusted EPS of $5.50 beating estimates and revenues of $17.5 billion growing 10.3% year-over-year. The company benefited from rising admissions and higher inpatient and outpatient surgeries, though rising expenses partially offset the positives.

  Zacks Investment Research

  Featured Companies: EHC HCA UHS
• Amphastar Pharmaceuticals: Buy When Fear Is Overblown

  Amphastar Pharmaceuticals' stock has fallen 31% in 5 months despite positive financials, and whether it presents a value investment. Read more here.

  Seeking Alpha
• Implied Volatility Surging for Amphastar (AMPH) Stock Options

  Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.

  Zacks Investment Research